Tectonic Therapeutic
Update in progressTECX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Tectonic Therapeutic, Inc. is a biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein–coupled receptors (GPCRs). It uses its GEODe platform to enable GPCR-targeted biologics. Its lead product, TX45, is an Fc-relaxin fusion that activates the RXFP1 receptor. The company is also developing TX2100 for hereditary hemorrhagic telangiectasia, a GPCR modulator bispecific for fibrosis, and other GPCR programs. Based in Watertown, Massachusetts.
Company score
- Sentiment
- 0.12
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.06
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!